About the Authors
Austin Cox, PharmD, is senior director of trade relations at Florida Cancer Specialists & Research Institute in Birmingham, Alabama.
Michael Reff, MBA, RPh, is executive director and founder of NCODA in Cazenovia, New York.
Publication
Article
Pharmacy Practice in Focus: Oncology
Author(s):
Medically integrated pharmacies improve collaboration, patient care, communication, and therapy management.
When looking at the implications of limited distribution drugs and rare disease drugs, it is important to discuss pharmacy models that can better support patients in navigating drug distribution networks. Patients do not know the variations they may encounter in having to fill prescriptions differently unless they have already experienced it. A patient-centric approach keeps individual perspectives and needs at the forefront and is imperative whenever looking at the best options.
Image credit: davit85 | stock.adobe.com
A medically integrated pharmacy (MIP) is a pharmacy model with access to the electronic medical record (EMR). Its staff and workflows are fully embedded within the practice, be it a community or health system setting. The record number of new FDA-approved oral medications with oncology indications has catalyzed tremendous adoption of the MIP model over the past decade, with other specialized fields now mirroring this structure. Integrating MIPs allows seamless collaboration between the pharmacy team and health care providers, fostering a more coordinated and comprehensive approach to patient care.
Overall, the MIP model aims to improve patient outcomes by ensuring that pharmacists are integral care team members, providing a more holistic, collaborative approach to medication management. This is especially critical for therapies that have AEs requiring clinical interventions. Pharmacists can empower patients to recognize symptoms, report issues, and stay engaged in their care with frequent touchpoints, ensuring timely refills and monitoring overall progress throughout their treatment.
Austin Cox, PharmD, is senior director of trade relations at Florida Cancer Specialists & Research Institute in Birmingham, Alabama.
Michael Reff, MBA, RPh, is executive director and founder of NCODA in Cazenovia, New York.
The MIP model stands out as a solution in patient-centered pharmacy care, offering unmatched support for individuals managing complex therapies. By fully integrating pharmacists into the care team, MIPs provide patients with a seamless, cohesive approach that fosters better outcomes, improves adherence, and strengthens overall patient satisfaction. This model enhances clinical oversight and personalized support and empowers patients with the tools and guidance they need to stay engaged in their treatment journey. For those facing the challenges of cancer or rare diseases, the MIP model delivers an essential layer of care, reinforcing our commitment to prioritizing patients’ well-being at every step. For health care providers, it is essential to keep patient needs as the focus—any other focus risks undermining the quality and effectiveness of the care we strive to provide.